[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 224, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 962226, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 775967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 48, "title": "Chief Business Officer, Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 596253, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.66, "open": 0.6791, "dayLow": 0.67, "dayHigh": 0.7272, "regularMarketPreviousClose": 0.66, "regularMarketOpen": 0.6791, "regularMarketDayLow": 0.67, "regularMarketDayHigh": 0.7272, "payoutRatio": 0.0, "beta": -0.36, "forwardPE": -0.83416665, "volume": 1077007, "regularMarketVolume": 1047372, "averageVolume": 1221732, "averageVolume10days": 1827870, "averageDailyVolume10Day": 1827870, "bid": 0.505, "ask": 0.8827, "bidSize": 2, "askSize": 2, "marketCap": 204717904, "fiftyTwoWeekLow": 0.509, "fiftyTwoWeekHigh": 3.256, "priceToSalesTrailing12Months": 3249.4905, "fiftyDayAverage": 0.63626, "twoHundredDayAverage": 1.35759, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -197686400, "profitMargins": 0.0, "floatShares": 190431251, "sharesOutstanding": 292161984, "sharesShort": 11525095, "sharesShortPriorMonth": 12314391, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0394, "heldPercentInsiders": 0.1372, "heldPercentInstitutions": 0.66643, "shortRatio": 14.5, "shortPercentOfFloat": 0.053200003, "impliedSharesOutstanding": 292161984, "bookValue": 2.068, "priceToBook": 0.33882976, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -203988992, "trailingEps": -0.79, "forwardEps": -0.84, "enterpriseToRevenue": -3137.879, "enterpriseToEbitda": 1.006, "52WeekChange": -0.7238494, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 0.7007, "targetHighPrice": 1.0, "targetLowPrice": 0.6, "targetMeanPrice": 0.8, "targetMedianPrice": 0.8, "recommendationMean": 3.25, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 440547008, "totalCashPerShare": 1.578, "ebitda": -196600000, "totalDebt": 58575000, "quickRatio": 13.146, "currentRatio": 13.429, "totalRevenue": 63000, "debtToEquity": 11.037, "revenuePerShare": 0.0, "returnOnAssets": -0.19115, "returnOnEquity": -0.33216, "grossProfits": 63000, "freeCashflow": -83122752, "operatingCashflow": -155787008, "revenueGrowth": 0.36, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -1485.4413, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 6.16666, "regularMarketPrice": 0.7007, "marketState": "POST", "corporateActions": [], "postMarketTime": 1740171613, "regularMarketTime": 1740171600, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": 0.0, "postMarketPrice": 0.7007, "postMarketChange": 0.0, "regularMarketChange": 0.04069996, "regularMarketDayRange": "0.67 - 0.7272", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1221732, "fiftyTwoWeekLowChange": 0.19169998, "fiftyTwoWeekLowChangePercent": 0.3766208, "fiftyTwoWeekRange": "0.509 - 3.256", "fiftyTwoWeekHighChange": -2.5553, "fiftyTwoWeekHighChangePercent": -0.7847973, "fiftyTwoWeekChangePercent": -72.38494, "epsTrailingTwelveMonths": -0.79, "epsForward": -0.84, "epsCurrentYear": -0.58, "priceEpsCurrentYear": -1.2081034, "fiftyDayAverageChange": 0.06444001, "fiftyDayAverageChangePercent": 0.10127938, "twoHundredDayAverageChange": -0.65689, "twoHundredDayAverageChangePercent": -0.48386478, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "3.3 - Hold", "cryptoTradeable": false, "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]